1-(2-氯苯基)-2-(4-氯苯基)乙酮 | 7504-29-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 1-(2-氯苯基)-2-(4-氯苯基)乙酮
• 英文名称: 1-(2-chlorophenyl)-2-(4-chlorophenyl)ethanone
• 英文别名: 2,4'-dichloro-deoxybenzoin；2,4'-Dichlor-desoxybenzoin；1-(2-chloro-phenyl)-2-(4-chloro-phenyl)-ethanone
• CAS: 7504-29-2
• 化学式: C₁₄H₁₀Cl₂O
• 分子量: 265.139
• InChiKey: HTDREFHTYBJGPB-UHFFFAOYSA-N

物化性质

• 熔点：
  65 °C
• 沸点：
  358.8±22.0 °C(Predicted)
• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-氯苯基)-2-(4-氯苯基)乙酮 在 phenyltrimethylammonium tribromide 作用下， 以 四氢呋喃 为溶剂， 反应 1.25h， 生成 2-bromo-1-(2-chlorophenyl)-2-(4-chlorophenyl)-ethanone
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

  摘要：

  这项发明涉及式(I)的化合物：其中X，Y，R1，R2，R3和R4如本文所述。该发明还涉及制备该化合物的方法及其治疗用途。

  公开号：

  US20080269303A1
• 作为产物：
  描述：

  邻氯苯甲酰氯 、 4-氯苄溴 在 四(三苯基膦)钯 锌 作用下， 以 乙二醇二甲醚 为溶剂， 以78%的产率得到1-(2-氯苯基)-2-(4-氯苯基)乙酮
  参考文献：
  名称：

  WO2006/131807

  摘要：

  公开号：

文献信息

• [EN] SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES<br/>[FR] DERIVES DE NAPHTYRIDINONE SUBSTITUES
  申请人：MERCK & CO INC

  公开号：WO2005047285A1

  公开（公告）日：2005-05-26

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或逆向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可作为中枢作用药物用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和吉兰-巴雷综合征）、病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖或进食障碍的治疗，以及治疗哮喘、便秘、慢性肠道假性梗阻和肝硬化。
• Tandem nucleophilic addition–Oppenauer oxidation of aromatic aldehydes to aryl ketones with triorganoaluminium reagents
  作者：Ying Fu、Yanshou Yang、Helmut M. Hügel、Zhengyin Du、Kehu Wang、Danfeng Huang、Yulai Hu

  DOI：10.1039/c3ob40642c

  日期：——

  In the presence of pinacolone, the in situ prepared triorganoaluminium reagents reacted with aromatic aldehydes to give ketones in moderate to high yield. We propose that the products are formed via a tandem organoaluminium reagents addition–Oppenauer oxidation sequence.

  在频哪酮的存在下，原位制备的三有机铝试剂与芳族醛反应，以中等至高收率得到酮。我们建议这些产物是通过有机铝串联试剂-Oppenauer氧化顺序形成的。
• HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：BARTH Francis

  公开号：US20080269303A1

  公开（公告）日：2008-10-30

  The invention concerns compounds of formula (I): Wherein X, Y, R 1 , R 2 , R 3 and R 4 are as described herein. The invention also concerns a method for preparing same and the therapeutic use thereof.

  这项发明涉及式(I)的化合物：其中X，Y，R1，R2，R3和R4如本文所述。该发明还涉及制备该化合物的方法及其治疗用途。
• Substituted furo[2,3-b]pyridine derivatives
  申请人：Toupence B. Richard

  公开号：US20050272763A1

  公开（公告）日：2005-12-08

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化和格林-巴利综合征）和病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• Substituted 2,3-diphenyl pyridines
  申请人：Finke E Paul

  公开号：US20050182103A1

  公开（公告）日：2005-08-18

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病，包括多发性硬化症和格林-巴利综合征，以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症，焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍以及哮喘、便秘、慢性肠假性梗阻和肝硬化。